Ceribell Inc. CEO Chao Xingjuan sold 6,068 shares of common stock on August 21, 2026, for a total of $145,753 at $24.02 per share. The transaction was executed to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs).
Following the sale, Xingjuan retains direct ownership of 781,731 shares, while her indirect holdings through the ACP 2021 Trust total 369,088 shares, excluding her pecuniary interest. The stock’s 52-week high stands at $25.33, and its year-over-year return has reached 109%. Ceribell’s gross profit margins are reported at 88.9%, with the company maintaining a cash position exceeding its debt load. InvestingPro analysis has classified the stock as overvalued relative to its Fair Value estimate.
The company reported Q2 2026 revenue of $28.1 million, a 33% increase year-over-year, accelerating from the 29% growth recorded in the prior quarter. However, the quarterly loss widened to $0.51 per share, exceeding analyst expectations of a $0.36 loss. Account growth totaled 32 during the period, slightly below Canaccord’s estimate of 36, attributed to strong same-store utilization.
Ceribell is expanding its product portfolio, advancing new offerings for delirium monitoring and pediatric care. The company also received FDA approval to broaden its on-label indication to include pediatric and neonatal applications. Analysts have adjusted price targets upward: Canaccord raised its target from $25 to $26 while maintaining a Buy rating, and BTIG increased its target from $28 to $30.
